|
|
|
|
| LEADER |
01000caa a22002652 4500 |
| 001 |
NLM162166281 |
| 003 |
DE-627 |
| 005 |
20240413231906.0 |
| 007 |
tu |
| 008 |
231223s2006 xx ||||| 00| ||eng c |
| 028 |
5 |
2 |
|a pubmed24n1374.xml
|
| 035 |
|
|
|a (DE-627)NLM162166281
|
| 035 |
|
|
|a (NLM)16631408
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Cuzzocrea, Salvatore
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Glycogen synthase kinase-3beta inhibition attenuates the degree of arthritis caused by type II collagen in the mouse
|
| 264 |
|
1 |
|c 2006
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ohne Hilfsmittel zu benutzen
|b n
|2 rdamedia
|
| 338 |
|
|
|a Band
|b nc
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 03.08.2006
|
| 500 |
|
|
|a Date Revised 12.04.2024
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a RetractionIn: Clin Immunol. 2024 May;262:110198. - PMID 38555221
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Recently, glycogen synthase kinase-3 (GSK-3) has being identified as an ubiquitous serine-threonine protein kinase that participates in a multitude of cellular processes and plays an important role in the pathophysiology of a number of diseases. The aim of this study was to investigate the effects of GSK-3beta inhibition on the degree of arthritis caused by type II collagen (CII) in the mouse (collagen-induced arthritis; CIA). Mice developed erosive hind paw arthritis when immunized with CII in an emulsion in complete Freund's adjuvant (CFA). The incidence of CIA was 100% by day 28 in the CII-challenged mice and the severity of CIA progressed over a 35-day period with radiographic evaluation revealing focal resorption of bone. The histopathology of CIA included erosion of the cartilage at the joint margins. Treatment of mice with the GSK-3beta inhibitor TDZD-8 (1 mg/kg/day i.p.) starting at the onset of arthritis (day 25) ameliorated the clinical signs at days 26-35 and improved histological status in the joint and paw. Immunohistochemical analysis for nitrotyrosine, poly(ADP-ribose) (PAR), inducible nitric oxide synthase (iNOS), and cyclooxygenase-2 (COX-2) revealed a positive staining in inflamed joints from mice subjected to CIA. The degree of staining for nitrotyrosine, PAR, iNOS, and COX-2 was significantly reduced in CII-challenged mice treated with the GSK-3beta inhibitor. Plasma levels of tumor necrosis factor (TNF)-alpha and the joint tissue levels of macrophage inflammatory protein (MIP)-1alpha and MIP-2 were also significantly reduced by GSK-3beta inhibition. These data demonstrate that GSK-3beta inhibition exerts an anti-inflammatory effect during chronic inflammation and is able to ameliorate the tissue damage associated with CIA
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Research Support, Non-U.S. Gov't
|
| 650 |
|
4 |
|a Retracted Publication
|
| 650 |
|
7 |
|a 4-benzyl-2-methyl-1,2,4-thiadiazolidine-3,5-dione
|2 NLM
|
| 650 |
|
7 |
|a Chemokine CCL3
|2 NLM
|
| 650 |
|
7 |
|a Chemokine CCL4
|2 NLM
|
| 650 |
|
7 |
|a Chemokine CXCL2
|2 NLM
|
| 650 |
|
7 |
|a Collagen Type II
|2 NLM
|
| 650 |
|
7 |
|a Interleukin-6
|2 NLM
|
| 650 |
|
7 |
|a Macrophage Inflammatory Proteins
|2 NLM
|
| 650 |
|
7 |
|a Monokines
|2 NLM
|
| 650 |
|
7 |
|a Protein Kinase Inhibitors
|2 NLM
|
| 650 |
|
7 |
|a Thiadiazoles
|2 NLM
|
| 650 |
|
7 |
|a Tumor Necrosis Factor-alpha
|2 NLM
|
| 650 |
|
7 |
|a 3-nitrotyrosine
|2 NLM
|
| 650 |
|
7 |
|a 3604-79-3
|2 NLM
|
| 650 |
|
7 |
|a Tyrosine
|2 NLM
|
| 650 |
|
7 |
|a 42HK56048U
|2 NLM
|
| 650 |
|
7 |
|a Nitric Oxide Synthase Type II
|2 NLM
|
| 650 |
|
7 |
|a EC 1.14.13.39
|2 NLM
|
| 650 |
|
7 |
|a Cyclooxygenase 2
|2 NLM
|
| 650 |
|
7 |
|a EC 1.14.99.1
|2 NLM
|
| 650 |
|
7 |
|a Poly(ADP-ribose) Polymerases
|2 NLM
|
| 650 |
|
7 |
|a EC 2.4.2.30
|2 NLM
|
| 650 |
|
7 |
|a Glycogen Synthase Kinase 3 beta
|2 NLM
|
| 650 |
|
7 |
|a EC 2.7.11.1
|2 NLM
|
| 650 |
|
7 |
|a Gsk3b protein, mouse
|2 NLM
|
| 650 |
|
7 |
|a EC 2.7.11.1
|2 NLM
|
| 650 |
|
7 |
|a Glycogen Synthase Kinase 3
|2 NLM
|
| 650 |
|
7 |
|a EC 2.7.11.26
|2 NLM
|
| 700 |
1 |
|
|a Mazzon, Emanuela
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Di Paola, Rosanna
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Muià, Carmelo
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Crisafulli, Concetta
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Dugo, Laura
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Collin, Marika
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Britti, Domenico
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Caputi, Achille P
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Thiemermann, Christoph
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 120(2006), 1 vom: 18. Juli, Seite 57-67
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnns
|
| 773 |
1 |
8 |
|g volume:120
|g year:2006
|g number:1
|g day:18
|g month:07
|g pages:57-67
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 120
|j 2006
|e 1
|b 18
|c 07
|h 57-67
|